Moderna's cancer vaccine meets its goals, but shares fall after data leak

Moderna announced that its experimental cancer vaccine met its goals, as it helped prevent recurrence or death in melanoma patients by 42% after two years. However, a partial data leak raised investor concerns, and the stock fell despite the positive results.

AI-written summary of 2 sources; every verified point is backed by a verbatim quote. How Iyan works

• The experimental vaccine helped prevent recurrence or death in melanoma patients by 42% after two years.

  «helped prevent the return of cancer or death in melanoma patients by 42% after two years»

  MarketWatch
• Coverage described what happened as a sell-off reaction when the news was announced, as the stock declined despite the positive results.

  «Questions of a ‘sell-the-news reaction.’»

  MarketWatch • CNBC on MSN
• A partial leak of the study data before its full publication led to a drop in Moderna's share price.

  «Moderna's stock fell even though the full data, released later Thursday, appeared positive»

  CNBC on MSN
• The full study data was published later on Thursday.

  «the full data, released later Thursday, appeared positive based on Wall Street expectations»

  CNBC on MSN

Iyan — See it for yourself. What changed in your world today, why it matters, and how we know.
How it works • Privacy • Terms